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OBJECTIVES We sought to evaluate the efficacy and safety of pulmonary vein (PV) isolation using
transvenous cryoablation for the treatment of atrial fibrillation (AF).
BACKGROUND Although electrical isolation of PVs with radiofrequency energy for the treatment of AF is
feasible, it is associated with a significant risk of PV stenosis. Cryoablation is a new alternative
therapy allowing ablation of tissue while preserving its underlying architecture.
METHODS In 52 patients with paroxysmal (n  45) or persistent (n  7) AF, PV isolation using the
CryoCor cryoablation system (CyroCor Inc., San Diego, California) with a 10F deflectable
transvenous catheter was performed as guided by ostial PV potentials. Cryoablation was
applied twice at each targeted site (2.5 to 5 min/application). Computed tomography (CT)
of the thorax was performed at baseline and at 3 and 12 months to evaluate for PV stenosis.
RESULTS All targeted PVs were completely isolated in 49 (94%) of 52 of patients. Of 152 PVs targeted,
147 (97%) were successfully isolated (mean 3.0 PVs isolated per patient). After a mean period
of 12.4  5.5 months of follow-up, 37 (71%) of 52 patients had no recurrence of AF or were
clinically improved, including 29 patients (56%) who had no recurrence of AF with (n  11)
or without the use of anti-arrhythmic drugs. At 3 and 12 months, the CT scan showed no
evidence of PV stenosis associated with cryoablation in any patients.
CONCLUSIONS Transvenous catheter cryoablation is an effective method to create PV electrical isolation for
the treatment of AF. A clinically satisfactory result can be achieved in 71% of patients with
AF, without the risk of PV stenosis. (J Am Coll Cardiol 2003;42:752–8) © 2003 by the
American College of Cardiology Foundation
Radiofrequency (RF) energy application, applied either
focally to eliminate the triggering foci in the pulmonary
veins (PVs) or circumferentially to isolate the PVs from the
left atrium, has resulted in a cure of atrial fibrillation (AF) in
50% to 70% of patients (1–5). However, the procedure with
RF energy has a significant risk of mortality and morbidity,
including systemic embolism (2% to 5%), PV stenosis (3%
to 8%), pericardial effusion, cardiac tamponade, phrenic
nerve paralysis, and pro-arrhythmia (intra-atrial re-entry
tachycardia) (4–12). Additionally, multiple procedures are
required in 9% to 49% of patients to achieve clinical efficacy,
highlighting the challenge to determine a successful acute
end point (4–6). Although RF energy has become the gold
standard for catheter ablation in the majority of cardiac
arrhythmias, PV ablation by heating has potential limita-
tions: 1) RF energy produces tissue disruption, which
increases the risk of perforation and thromboembolism
(9,13); and 2) RF energy induces inhomogeneous, dense
fibrosis and shrinking of the tissue, leading to PV stenosis
(5–8,10,11,14). Therefore, evaluation of new energy sources
that may overcome these limitations is of clinical impor-
tance.
One such alternative energy source is cryothermal energy.
Previous clinical studies regarding the surgical treatment of
arrhythmias have demonstrated that cryoablation is a safe
and effective method for ablating cardiac tissues (15,16).
Pathologic studies in animals (17,18) and humans (19) have
shown that cryolesions are well delineated, transmural,
homogeneous, and without inflammation. Cryothermal en-
ergy creates minimal endothelial/endocardial disruption and
preserves the underlying tissue architecture. Therefore, the
lesions are minimally thrombogenic and arrhythmogenic,
and cryoablation of the PV should have a low risk of PV
stenosis (16). The advent of percutaneous catheter cryoab-
lation, which avoids the risks associated with open-heart
surgery (20), may provide an important alternative to RF
ablation for the treatment of AF. The initial early results of
a novel catheter-based cryoablation system (CryoCor Inc.,
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San Diego, California) for the treatment of supraventricular
tachycardias, including AF, have been reported recently
(21). In this report, we present the long-term results in
patients treated with this catheter cryoablation technique to
isolate PVs for the treatment of AF, with particular empha-
sis on the potential of this technique to avoid PV stenosis.
METHODS
Patient population. The subjects of this prospective study
consisted of 52 patients enrolled consecutively at three
participating clinical centers. Forty-one were men, with a
mean age of 50  11 years. Atrial fibrillation was paroxys-
mal in all patients during the initial enrollment for this
study; however, AF became persistent (defined as present
for 1 month and requiring cardioversion for termination)
in seven patients by the time of the procedure. A mean
number of 2.0  1.1 anti-arrhythmic drugs had been
ineffective in preventing AF recurrence before the proce-
dure. Twenty-eight patients (54%) had no structural heart
disease, 17 had arterial hypertension, 5 had coronary artery
disease, 1 had dilated cardiomyopathy, and 1 had valvular
heart disease. The mean left ventricular ejection fraction was
0.61  0.08 (range 0.39 to 0.82), and the mean left atrial
size was 4.0  0.7 cm (range 2.1 to 5.2 cm).
Patients were included if they had symptomatic AF
resistant to 2 anti-arrhythmic drugs and at least two
documented AF episodes within six weeks preceding the
procedure. There was a mean value of 11  11 episodes of
AF per month in patients with paroxysmal AF, as docu-
mented by a transtelephonic event recorder one month
before the procedure. Eight patients had previously failed
RF ablation of ectopic foci originating from the PVs.
Electrophysiologic procedure. Patients enrolled signed a
written consent form that was approved by the local ethics
committee. Before the procedure, all patients were orally
anticoagulated to a therapeutic international normalized
ratio of 2 to 3 for at least three weeks and had a transesoph-
ageal echocardiogram to exclude the presence of a left atrial
thrombus. Patients with persistent AF were converted to
sinus rhythm by internal or external cardioversion during
the procedure. In each patient, a decapolar catheter was
positioned in the distal coronary sinus to record, pace, and
confirm entrance conduction into the left PVs. Double
trans-septal catheterization was performed, and intravenous
heparin was administrated to achieve an activated clotting
time of 250 s. Venograms of all targeted PVs were
obtained both before and after the ablation procedure. A
deflectable, circumferential decapolar mapping catheter
(Lasso, Biosense-Webster Inc., Baldwin Park, California)
was advanced into the left atrium and positioned at the
ostium of each PV. A deflectable, 10F cryoablation catheter
(CryoCor Inc.) was inserted into the left atrium through a
10F to 12F, 65-cm-long sheath (DAIG, St. Jude Medical
Inc., St. Paul, Minnesota, or Cook Inc., Bloomington,
Indiana) and was used to perform the ablation.
Cryoablation procedure. Segmental isolation of PVs, as
guided by the recording of PV potentials with the Lasso
catheter, was performed using the CryoCor cryoablation
system (4,22). Whenever feasible, all PVs with PV poten-
tials recorded at their ostium were targeted for isolation.
Isolation of the PV was performed during sinus rhythm or
coronary sinus pacing by delivering cryoablation at ostial
sites that had the earliest bipolar potential. At each effective
target site, defined by the abolishment of a PV potential or
a change in the PV potential activation sequence during
cryothermal application, 2.5 to 5 min of cryoablation was
delivered twice (Fig. 1). If no changes in the electrogram
were observed after 45 s, despite a catheter tip temperature
of 70°C, the application was stopped and the catheter
was repositioned. The early procedural end point was
complete electrical isolation of PVs based on abolition of all
ostial PV potentials or complete entrance conduction block
into the PV (Fig. 2).
Post-ablation management. All patients were monitored
for 24 to 48 h and received anticoagulant therapy (warfarin)
and the same anti-arrhythmic drugs as before the ablation
for at least 3 months after the procedure. After three
months, the continuation of anti-arrhythmic drugs and
anticoagulation was left to the discretion of the physician.
Spiral computed tomographic (CT) scan. A contrast-
enhanced spiral CT scan of the thorax with three-
dimensional reconstruction was performed within 1 month
before the ablation procedure and at 3 and 12 months
follow-up to define the anatomy of the PVs and to measure
the diameter of the ostia of the PVs (Fig. 3). The same
radiologist (B.G.) reviewed all pre- and post-cryoablation
images in a blinded manner. The diameter of the ostia of the
PVs was determined for each patient in a pairwise manner
to maintain consistency in the measurements. In addition,
the radiologist was asked to indicate the presence, location,
and degree of any discrete luminal narrowing observed. All
measurements were made both for treated and untreated
veins to compare inter-observation variability.
Follow-up. The patients were seen in the outpatient clinic
every four to six weeks and then every two to three months
after the procedure. All patients were given an event
monitor recorder to document the frequency of symptom-
atic AF episodes. A successful outcome was defined as no
recurrence of symptomatic AF in the most recent six
months of follow-up, independent of treatment with an
anti-arrhythmic drug that had been ineffective before the
Abbreviations and Acronyms
AF  atrial fibrillation
CT  computed tomography
LIPV  left inferior pulmonary vein
LSPV  left superior pulmonary vein
PV  pulmonary vein
RF  radiofrequency
RIPV  right inferior pulmonary vein
RSPV  right superior pulmonary vein
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Figure 1. Isolation of the left superior pulmonary vein (PV). A decapolar ring catheter (PV1-2 to PV10-1) is positioned at the ostium of the left superior
PV. Recordings of the surface electrocardiographic leads I, aVL, and V1 and the cryoablation catheter (CryoDis) are shown during distal coronary sinus
(CSDis) pacing. After initial cryoablation applications at the earliest activation sites (*) of the PV potential at electrodes 9-10 (Baseline), the PV activation
sequence changes and the local endocardial activation time at electrodes 9-10 increases from 60 to 130 ms (Cryo9-10). Further cryoablation applications at
the earliest activation sites (*) of the PV potential at electrodes 3-4 resulted in complete electrical isolation without any PV potential (Cryo3-4).
Figure 2. An example of exit block of the pulmonary vein (PV) potential after isolation of the left inferior PV using cryoablation. Isolation of the PV is
confirmed by abolition (but there are still potentials visible) of all PV potentials as recorded by the decapolar ring catheter (PV1-2 to PV10-1). Exit block
of the PV potential (arrow) is observed during spontaneous discharge inside the PV. CSDis  distal coronary sinus; CryoDis  cryoablation catheter.
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ablation. Patients who had at least a 50% reduction of AF
episodes (frequency multiplied by average episode duration)
in the most recent six months on event recordings, com-
pared with the month before ablation, were considered
clinically improved.
Statistical analysis. Continuous measures are expressed as
the mean value  SD and were compared with a t test for
paired or unpaired data, as appropriate. Dichotomous vari-
ables were compared using the chi-square test with Yates’
correction. The CT data were compared using two-way
analysis of variance to detect the effect of vein size, treat-
ment, and follow-up duration. Statistical significance was
set at p  0.05.
RESULTS
Cryoablation of PVs. Successful electrical isolation was
achieved in 147 (97%) of the 152 targeted veins. These
included 48 (96%) of 50 left superior pulmonary veins
(LSPVs), 44 (96%) of 46 right superior pulmonary veins
(RSPVs), 38 (97%) of 39 left inferior pulmonary veins
(LIPVs), and 17 (100%) of 17 right inferior pulmonary
veins (RIPVs) in which isolation was attempted. There were
no significant differences in the efficacy of the vein isolation
procedure across the PVs (p  0.05). All targeted PVs were
completely isolated in 49 (94%) of the 52 patients with an
average of 3.0  0.9 veins treated per patient. The reasons
for failure to completely isolate the targeted PVs were
transient phrenic nerve paralysis in one patient and the
inability to maintain stable sinus rhythm in two patients
with persistent AF. The mean procedure time was 7.5 
2.0 h (range 3.5 to 13 h), and the mean fluoroscopic time
was 114  44 min (range 44 to 263 min). In one patient in
whom cryoablation did not successfully isolate all veins with
PV potentials due to the console failure, RF ablation of the
LIPV was performed at the index procedure.
A mean of 48.3  16.6 (range 10 to 79) cryoablation
applications were delivered per patient, and there was a
median of 13.9 (range 4.3 to 26) applications per vein (7.7
 2.3 sites). The overall mean percentage of effective
cryoablation applications was 70  15% (range 43% to
100%). The mean temperature achieved at target sites
during effective applications (77.5  4.5°C) was signifi-
cantly lower than that during ineffective applications (71.2
 5.0°C, p  0.01). The mean number of cryoablation
applications needed to achieve isolation of the LIPV (7.7 
4.4) and the RIPV (7.6  6.3) was significantly lower than
that for the LSPV (12.5  5.9, p  0.05) and RSPV (10.1
 5.2, p  0.05).
Follow-up results. After a mean follow-up of 12.4  5.5
months (range 1 to 19.8 months), 29 (56%) of 52 patients
had no recurrence of AF. Eighteen (62%) of these 29
patients were not taking anti-arrhythmic drugs at the time
of the last follow-up. At 12 months of follow-up, 16 (62%)
of 26 patients had no recurrence of AF. In patients with
paroxysmal AF, 26 (58%) of 45 patients were free of
arrhythmia, including 16 off anti-arrhythmic drugs. In
patients with persistent AF, successful long-term AF con-
trol was achieved in 3 (43%) of 7 patients, including 2
patients off anti-arrhythmic drugs.
The remaining 23 patients had one or more recurrences
of AF, with or without concomitant atrial flutter, identified
by the patient symptom report and/or by an event recorder
electrocardiogram. When AF recurred, it occurred with a
median time to the first recurrence of 2 days (range 1 to 21
Figure 3. Three-dimensional reconstruction of pulmonary veins (PVs) using a contrast-enhanced spiral computed tomography scan. The diameters of the
ostia of the left superior pulmonary vein (LSPV), right superior pulmonary vein (RSPV), left inferior pulmonary vein (LIPV), and right inferior pulmonary
vein (RIPV) are shown.
755JACC Vol. 42, No. 4, 2003 Tse et al.
August 20, 2003:752–8 Catheter Cryoablation of PVs
days). Of the 23 patients, 7 additional patients were clini-
cally improved after the cryoablation procedure and were
having at least a 50% reduction in the frequency and
duration of episodes while taking previously ineffective
anti-arrhythmic drugs (mean improvement 72  15%,
median 73%, range 50% to 98%). Using the same criteria of
frequency and duration, the remaining 15 patients had
improvement no better than a 15% reduction in AF epi-
sodes (mean 4  4%, median 0%, range 0% to 15%). Based
on these criteria, 37 (71%) of the 52 patients had adequate
control of their arrhythmia after the cryoablation procedure.
Five patients underwent a repeat cryoablation procedure.
One patient had a residual PV potential at the ostium of the
LSPV and RSPV, proximal to the previous ablation sites.
Both PVs were completely isolated at a more proximal site
by cryoablation. In one patient, foci outside the PVs, at the
superior vena cava, and at the ostium of the coronary sinus
were found. The third patient had one vein with recurrence
of PV potentials. All three patients had successful cryoab-
lation. Two patients developed a typical atrial flutter and
underwent successful cavo-tricuspid isthmus cryoablation. Af-
ter a repeated procedure, one patient had no episodes in the
most recent six months of follow-up, and the remaining four
patients were clinically improved as of the last follow-up.
PV stenosis. There was no acute PV stenosis or thrombosis
observed in any treated PVs, based on the second venogram
performed after the procedure. All patients were questioned
for symptoms of PV stenosis at 3, 6, and 12 months of clinic
follow-up. Only three patients reported symptoms sugges-
tive of PV stenosis during follow-up—namely, shortness of
breath (n  2) or a new cough (n  1). All three patients
underwent a lung perfusion scan to determine possible
stenosis. Of the three patients, one was diagnosed with a
pulmonary embolus (see Complications section), and the
other two had no anomalies on the scan. Furthermore, these
three patients did not have evidence of PV stenosis noted on
the CT scan obtained at the next follow-up interval.
All patients had a spiral CT scan performed before the
procedure; 47 (96%) of 49 patients and 19 (73%) of 26
patients who completed 3 and 12 months of follow-up,
respectively, had a repeated CT scan obtained. In 7 patients,
a repeated CT scan was not performed at 3 (n  3) and 12
months (n  7) of follow-up because of allergic reactions to
contrast agents on their baseline scan (n 2), patient refusal
(n  3), and performance of the surgical maze procedure (n
 2 at 3 and 5 months of follow-up). A transesophageal
echocardiogram was performed in those showing no in-
crease in Doppler flow at the PVs suggestive of stenosis. In
3 patients, 3 CT scans (1 at 3 months and 2 at 12 months)
were only evaluated by the local center due to technical
difficulties in transferring these scans to the core laboratory
facility. At the local center, no luminal irregularities or
narrowing were observed in these three patients; however,
their data are not included in the summary data presented
subsequently.
A total of 196 PVs were evaluated, of which 123 (63%)
had cryoablation performed. The mean diameter of all the
treated PVs was 15.5  3.6 mm (n  123) before the
procedure, 15.2  3.6 mm (n  123) at 3 months of
follow-up, and 14.6  3.6 mm (n  46) at 12 months of
follow-up (p  0.32). In 17 patients who had paired CT
data at 3 and 12 months, there were no significant differ-
ences in the percent change in PV diameter between the
treated and untreated PVs (n  28) at 3 months (2.5 
10.3% vs. 0.7  10.3%, p  0.47) and 12 months of
follow-up (6.6  12.9% vs. 9.4  15.0%, p  0.41). As
analyzed by two-way analysis of variance for time and
treatment effect, there were also no changes in the PV ostial
diameter due to the treatment effect noted (p  0.05), and
over time, both treated and untreated PVs significantly
decreased in size (p  0.05) (Fig. 4).
Regarding the anatomic positions of treated PVs, the
ostial diameter of the LSPV (n  41; 17.3  3.8 mm),
RSPV (n  35; 15.9  2.2 mm), and RIPV (n  14; 15.8
 3.4 mm) was significantly larger than that of the LIPVs
(n  33; 12.9  3.3 mm; p  0.05) on the baseline CT
scan. At 3 and 12 months of follow-up, there were no
significant serial changes in the ostial diameters of the
LSPVs (17.0 3.6 mm vs. 16.7 3.5 mm after 12 months
[n 16]; p 0.05), RSPVs (15.3 2.4 mm vs. 14.7 2.6
mm after 12 months [n  15]; p  0.05), LIPVs (12.4 
3.3 mm vs. 11.3  2.5 mm after 12 months [n  12]; p 
0.05), and RIPVs (15.5  2.9 mm vs. 16.6  1.5 mm after
12 months [n  3]; p  0.05) (Fig. 5).
Three PVs in three patients were reported to have
discrete luminal narrowing of25%, noted both before and
after cryoablation, and remained unchanged through
follow-up. These luminal irregularities were likely caused by
previous RF ablation (n  2) or an anatomic variant (n 
1). In one patient who received both RF and cryoablation in
the index procedure, 75% narrowing was noted in the LIPV,
which was treated with RF alone. No significant narrowing
was noted in the LSPV, a vein that was treated with
cryoablation. Otherwise, there was no evidence of discrete
luminal irregularities, generalized narrowing, or other signs
of stenosis in any other treated PVs.
Figure 4. Serial changes in the diameter of the ostia of the treated (solid
bars) and untreated (open bars) pulmonary veins (PVs), as measured by a
computed tomography scan of the thorax at baseline and 3 months (3M)
and 12 months (12M) of follow-up.
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Complications. Some of the early procedure-related com-
plications have been reported previously (21). One patient
had a peri-procedural ischemic event with left-sided hemi-
plegia, occurring at the end of the procedure during PV
angiography. After 12 months of follow-up, his neurologic
status had significantly recovered. One patient with a
history of coronary artery bypass surgery developed a pul-
monary embolism two months after the procedure. During
this event, the patient was inadequately anticoagulated.
Another patient developed an arteriovenous fistula that
required surgical repair. Finally, one patient had transient
phrenic nerve paresis during a cryoablation application in
the RSPV, resulting in premature procedure termination.
However, the diaphragmatic movement resumed immedi-
ately after termination of cryoablation without sequelae, and
there was no damage of the phrenic nerve or loss of
diaphragmatic or pulmonary function at 12-month
follow-up.
DISCUSSION
The data presented herein show that the novel cryoablation
system used in this study allows for the percutaneous
delivery of cryothermal energy and is a safe and effective way
to perform segmental isolation of PVs for the treatment of
AF, without the risk of PV stenosis during long-term
follow-up.
Early electrical isolation of PVs, as determined by elim-
ination of all PV potentials and entrance block into the PV,
was achieved in 97% of the PVs targeted. During long-term
clinical follow-up, 71% of patients with AF had no recur-
rence of symptomatic episodes or were clinically improved
(including 56% without any recurrence of AF), suggesting
that cryoablated lesions result in not only short-term but
also permanent electrical isolation of PVs. This is consistent
with a recent animal study in which catheter cryoablation
could effectively create circumferential lesions (averaging 18
mm in length and 13 mm in width) in the PV (23). In the
present study, the long-term clinical efficacy of PV isolation
using cryoablation has a 56% success rate, with only 10% of
patients undergoing a repeat ablation procedure. This result
is comparable to the clinical efficacy of previous studies
using RF energy for segmental isolation of PVs (50% to
70%) (4,5,23). However, the prevalence of anti-arrhythmic
drug use (38%) in those patients free of arrhythmia recur-
rence remains high. In this multicenter study, the long-term
use of anti-arrhythmic drugs was not controlled. One
possible explanation for the reluctance of stopping anti-
arrhythmic drugs in some patients, even if they were free of
arrhythmia, is due to the high percentage of patients having
underlying structural heart disease (46%) and a large per-
centage of patients in whom a previous PV ablation proce-
dure with RF energy had failed (15%) or who had persistent
AF (13%).
Most important is the difference in the safety profile for
cryoablation. The overall procedure complication rate, ex-
cluding PV stenosis, of 7.7% (4 of 52 patients) is lower than
the rate range (8% to 35%) of voluntarily reported compli-
cations in noncontrolled trials using RF energy (1–6,9). In
this study, one patient (2%) developed a thromboembolic
event associated with PV ablation, and this incidence is
similar to previous studies using RF energy (1,4,9,10).
Although cryoablation may be associated with a lower
thrombogenic tendency than RF energy (24,25), the throm-
boembolic risk related to left atrial catheter ablation re-
mains. Like RF ablation (9), cryoablation can produce
phrenic nerve paralysis. Therefore, identification of dia-
grammatic movement during pacing with a high current
from the tip of the catheter before PV ablation, especially
the RSPV, is recommended. As seen in this study, one of
the advantages of the use of cryoablation for PV isolation is
that phrenic nerve function recovers after stopping the
cryoapplication, which is a form of “ice mapping” for
complications.
Most interestingly is the lack of any short- or long-term
PV stenosis in the present study. Despite the use of an
electroanatomic mapping technique, intracardiac echocardi-
ography, and biplane fluoroscopy to guide the positioning of
the mapping and ablation catheters at the PV ostium, up to
5% of patients developed severe PV stenosis after RF
ablation (12,26). Patients with severe PV stenosis after RF
ablation often presented with respiratory symptoms that
frequently led to a misdiagnosis of other common diseases,
resulting in erroneous diagnostic and therapeutic proce-
dures. Furthermore, a significant proportion of patients
remained symptomatic or developed restenosis after the PV
intervention for PV stenosis (12). These highlight: 1) the
difficulty in defining the most proximal extent of the ostium
during PV isolation and effectively isolating all the PVs
using RF energy without causing PV stenosis; and 2) the
importance of preventing PV stenosis. In the study reported
herein, no patients had either physiologic or anatomic PV
stenosis as the result of cryoablation. Three patients did
have luminal irregularities that were the result of a previous
(n  2) or concomitant (n  1) RF ablation procedure.
Figure 5. Serial changes in the diameter of the ostia of the treated left
superior pulmonary vein (LSPV), right superior pulmonary vein (RSPV),
left inferior pulmonary vein (LIPV), and right inferior pulmonary vein
(RIPV), as measured by a computed tomography scan of the thorax at
baseline (B) and 3 months (3M) and 12 months (12M) of follow-up.
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Study limitations. The first limitation of this study is that
the clinical efficacy of the procedure was based on the
documentation of symptomatic recurrences of AF. Asymp-
tomatic episodes of AF were not assessed routinely by
ambulatory monitoring during follow-up. However, because
all of the patients in this study were highly symptomatic
before the ablation, no recurrence of their symptomatic AF
was considered an acceptable clinical end point. Secondly,
the mean procedure and fluoroscopy times necessary for PV
isolation were long, although they were still within accepted
safe ranges (27). The longer procedure times were due, on
the one hand, to the nature of this technique (cryoablation
requires longer individual ablation applications of 2.5 to 5
min), a learning curve in the use of this new technique for
PV isolation, and, on the other hand, to the additional
protocol-oriented procedures (transesophageal echocardiog-
raphy was used during the procedure by one center and PV
angiography before and after cryoablation was mandated by
the protocol). Additionally, in some patients, a three-
dimensional mapping system was used, further prolonging
the procedure in these patients. The procedure and fluoros-
copy times will decrease as operators gain experience using
this system, with a shorter ablation protocol and further
refinement of the catheter designs, such as the use of a
balloon catheter to occlude the blood flow of the PV during
ablation to improve the efficacy of each cryoablation appli-
cation. Finally, an electrocardiogram-triggered measure-
ment was not used to determine the PV diameter during
CT scanning in this study. Although this might have
affected the measurement of the PV luminal diameter, there
was no evidence of discrete luminal irregularities, general-
ized narrowing, or clinical signs of stenosis in any cryoab-
lated PVs, and this would impart an error in the measure-
ment of both treated and untreated veins equally.
Conclusions. Our results suggest that electrical isolation of
the PVs using cryoablation is feasible and may prevent
arrhythmia recurrence in patients with AF, without the
occurrence of PV stenosis over long-term follow-up.
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